Dr. Pengcheng Zhou Joins Cure Genetics as Vice Pre...
2023.10.10
Dr. Pengcheng Zhou Joins Cure Genetics as Vice Pre...
Cure Genetics is delighted to announce that Dr. Pengcheng Zhou has joined the company on August 21, 2023, taking on the role of Vice President of Gene Therapy Research and Development, responsible for the research and translation of the company's gene therapy products. Dr. Zhou brings with him decades of extensive experience in the AAV gene therapy domain, showcasing remarkable achievements at leading academic institutions and renowned companies including Harvard University, Voyager, Luye Pharma, and Frontera Therapeutics.

More

>
Dr. Ren Li Appointed Chief Technology Officer at C...
2023.09.15
Dr. Ren Li Appointed Chief Technology Officer at C...
Cure Genetics is delighted to announce that Dr. Li Ren has joined the company recently, taking on the role of Chief Technology Officer in Cell Therapy.

More

>
Cure Genetics and Frametact Limited Enter collabor...
2023.09.14
Cure Genetics and Frametact Limited Enter collabor...
Cure Genetics and Frametact Limited, a biotech company specializing in researching and developing treatments for neurological diseases, jointly announce the signing of a collaborative development and licensing agreement.

More

>
Dr. Shawn He Named Chief Scientific Officer at Cur...
2023.08.01
Dr. Shawn He Named Chief Scientific Officer at Cur...
Cure Genetics is delighted to announce that Dr. Shawn He will officially take up his post as the Chief Scientific Officer (CSO) in cell therapy on August 1, 2023. Shawn will guide the navigation of Cure Genetics' cell therapy development, leading the team to break new ground and accelerate the progress of cell therapy pipelines.

More

>
Cure Genetics and Frametact Reach a $60 Million Co...
2023.09.14
Cure Genetics and Frametact Reach a $60 Million Co...
Cure Genetics and Frametact Limited jointly announce the signing of a collaborative development and licensing agreement. The partnership will leverage Cure Genetics' proprietary VELPTM platform to develop novel Adeno-Associated Virus (AAV) vectors for the treatment of familial neurological diseases.

More

>